The estimated Net Worth of Eleanor Ramos is at least $5.64 Milhão dollars as of 3 December 2021. Eleanor Ramos owns over 5,201 units of Provention Bio stock worth over $1,748,600 and over the last 9 years he sold PRVB stock worth over $0. In addition, he makes $3,888,960 as Chief Medical Officer at Provention Bio.
Eleanor has made over 5 trades of the Provention Bio stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,201 units of PRVB stock worth $33,754 on 3 December 2021.
The largest trade he's ever made was buying 11,000 units of Provention Bio stock on 17 August 2015 worth over $230,230. On average, Eleanor trades about 1,313 units every 144 days since 2015. As of 3 December 2021 he still owns at least 70,000 units of Provention Bio stock.
You can see the complete history of Eleanor Ramos stock trades at the bottom of the page.
Dr. Eleanor L. Ramos M.D. serves as Chief Medical Officer of the Company. Dr. Ramos joined Provention in July 2017 and is its Chief Medical Officer. Dr. Ramos’ background includes significant clinical expertise in autoimmunity, inflammation, organ transplant rejection and the treatment of acute and chronic viral infections. Prior to joining Provention, Dr. Ramos served as a Chief Medical Officer of Global Blood Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapeutics to treat blood-based and hypoxemic pulmonary disorders from 2014 to 2016. Her past experience includes roles as Chief Medical Officer of Theraclone Sciences, a therapeutic antibody discovery and development company, where she oversaw the development of clinical programs in viral diseases including severe influenza from 2011 to 2014, and as Chief Medical Officer at ZymoGenetics, Inc., overseeing its clinical portfolio across infectious diseases/hepatitis C, immunology/lupus nephritis, oncology and hemostasis from 2009 to 2011. Dr. Ramos is currently a member of the Scientific Advisory Board of EpiVax Oncology, a private biotechnology company focused on developing personalized cancer vaccines, and a member of the Board of Directors of ASK, a non-profit organization dedicated to increasing awareness of lung cancer in women, particularly those of Asian descent. Her experience also encompasses leading the Clinical Trials Group at the Immune Tolerance Network, a collaborative network for clinical research funded by the National Institute of Allergy and Infectious Diseases. She holds a medical degree and undergraduate degree from Tufts University, along with advanced training in the subspecialty of nephrology with a focus on transplantation immunology at Brigham and Women’s Hospital, Harvard Medical School.
As the Chief Medical Officer of Provention Bio, the total compensation of Eleanor Ramos at Provention Bio is $3,888,960. There are 1 executives at Provention Bio getting paid more, with Ashleigh Palmer having the highest compensation of $3,959,460.
Eleanor Ramos is 64, he's been the Chief Medical Officer of Provention Bio since 2017. There are 4 older and 13 younger executives at Provention Bio. The oldest executive at Provention Bio, Inc. is Avery Catlin, 72, who is the Independent Director.
Eleanor's mailing address filed with the SEC is C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK, NJ, 07701.
Over the last 6 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski, eAvery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Provention Bio executives and other stock owners filed with the SEC include: